Tyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback.Company plans to submit IND in June 2026 for ...

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans ...

Please provide your email address to receive an email when new articles are posted on . Patients with COPD experienced early, but modest and nonpersistent, reductions in lung function during treatment ...

Hypercapnic patients were best separated from normocapnic patients using thresholds for FVC% of 56% predicted and 33% predicted for FEV1%. Hypercapnia in patients with chronic obstructive pulmonary ...

COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes breathing ...

Background Preterm birth is associated with lifelong respiratory sequelae, yet our understanding of lung function trajectories across the lifespan remains limited. We aimed to identify patterns of ...

Supported by an independent educational grant from Boehringer Ingelheim and Pfizer. Mrs. Sweet is a 51-year-old woman who presents to your office with the chief complaint of shortness of breath and ...

Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need ...